

1

2

3 1. A method for the treatment and/or prophylaxis of  
4 cardiovascular diseases <sup>and/or atherosclerosis</sup> or eating disorders in a human or  
5 non-human mammal, which comprises administering to said  
6 human or non-human mammal in need thereof, an effective,  
7 non-toxic amount of a compound of formula (I):

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32


33

34

35

36

37



(I)

14

15 or a tautomeric form thereof and/or a pharmaceutically  
16 acceptable salt thereof and/or a pharmaceutically  
17 acceptable solvate thereof, wherein:

18

19 A<sup>1</sup> represents a substituted or unsubstituted aromatic  
20 heterocyclyl group;

21

22 R<sup>1</sup> represents a hydrogen atom, an alkyl group, an acyl  
23 group, an aralkyl group, wherein the aryl moiety may be  
24 substituted or unsubstituted, or a substituted or  
25 unsubstituted aryl group;

26 R<sup>2</sup> and R<sup>3</sup> each represent hydrogen, or R<sup>2</sup> and R<sup>3</sup> together  
27 represent a bond;

28 A<sup>2</sup> represents a benzene ring having in total up to five  
29 substituents; and

30 n represents an integer in the range of from 2 to 6.


31

32 2. A method according to claim 1, wherein A<sup>1</sup> in the  
33 compound of formula (I) represents a substituted or  
34 unsubstituted, single or fused ring aromatic heterocyclyl  
35 group comprising up to 4 hetero atoms in the ring  
36 selected from oxygen, sulphur or nitrogen.


37

1 3. A method according to claim 1, wherein A<sup>1</sup> in the  
2 compound of formula (I) represents a moiety of formula (a),  
3 (b) or (c):


4



10 (a)



(b)



(c)

14 wherein:

15 R<sup>4</sup> and R<sup>5</sup> each independently represents a hydrogen atom, an  
16 alkyl group or a substituted or unsubstituted aryl group or  
17 when R<sup>4</sup> and R<sup>5</sup> are each attached to a carbon atom, then R<sup>4</sup>  
18 and R<sup>5</sup> together with the carbon atoms to which they are  
19 attached form a benzene ring wherein each carbon atom  
20 represented by R<sup>4</sup> and R<sup>5</sup> together may be substituted or  
unsubstituted; and in the moiety of formula (a)  
X represents oxygen or sulphur.


21

22 4. A method according to claim 3, wherein R<sup>4</sup> and R<sup>5</sup> in  
23 (a), (b) or (c) each independently represent hydrogen, alkyl  
24 or a substituted or unsubstituted phenyl group.

25

26 5. A method according to claim 3, wherein R<sup>4</sup> and R<sup>5</sup> in  
27 (a), (b) or (c) together represent a moiety of formula (d):

28



32 (d)

33

1 wherein R<sup>6</sup> and R<sup>7</sup> each independently represent hydrogen,  
 2 halogen, substituted or unsubstituted alkyl or alkoxy.

3


4 6. A method according to claim 5, wherein R<sup>6</sup> and R<sup>7</sup> in  
 5 (d) each represent hydrogen.

6

7 7. A method according to claim 1, wherein A<sup>2</sup> in the  
 8 compound of formula (I) represents a moiety of formula (e):

9

10



(e)

11

12

13

14 wherein R<sup>8</sup> and R<sup>9</sup> each independently represent hydrogen,  
 15 halogen, substituted or unsubstituted alkyl or alkoxy.

16

17 8. A method according to claim 7, wherein R<sup>8</sup> and R<sup>9</sup> in  
 18 (e) each represent hydrogen.

19

20 9. A method according to claim 1, of formula (II):

21

22

23


24

25

26

27

28



(II)

29

30

31 or a tautomeric form thereof and/or a pharmaceutically  
 32 acceptable salt thereof and/or a pharmaceutically acceptable  
 33 solvate thereof, wherein A<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and n are as defined  
 34 in relation to formula (I) in claim 1 and R<sup>8</sup> and R<sup>9</sup> are as  
 35 defined in relation to formula (e) in claim 7.

36

1 10. A method according to claim 1, wherein n in the  
2 compound of formula (I) represents an integer 2 or 3.

3

4 11. A method according to claim 1, wherein R<sup>1</sup> in the  
5 compound of formula (I) represents a methyl group.

6

7 12. A method according to claim 1 which comprises the  
8 administration of a compound selected from the group  
9 consisting of:

10

11 5-(4-[2-(N-methyl-N-(2-benzothiazolyl)amino)ethoxy]  
12 benzyl)-2,4-thiazolidinedione;

13

14 5-(4-[2-(N-methyl-N-(2-benzothiazolyl)amino)ethoxy]  
15 benzylidene)-2,4-thiazolidinedione;

16

17 5-(4-[2-(N-methyl-N-(2-benzoxazolyl)amino)ethoxy]  
18 benzyl)-2,4-thiazolidinedione;

19

20 5-(4-[2-(N-methyl-N-(2-benzoxazolyl)amino)ethoxy]  
21 benzylidene)-2,4-thiazolidinedione;

22

23 5-(4-[2-(N-methyl-N-(2-pyrimidinyl)amino)ethoxy]  
24 benzyl)-2,4-thiazolidinedione;

25

26 5-(4-[2-(N-methyl-N-(2-pyrimidinyl)amino)ethoxy]  
27 benzylidene)-2,4-thiazolidinedione;

28

29 5-(4-(2-(N-methyl-N-[2-(4,5-dimethylthiazolyl)]amino)  
30 ethoxy]benzyl)-2,4-thiazolidinedione;

31

32 5-(4-[2-(N-methyl-N-[2-(4,5-dimethylthiazolyl)]amino)  
33 ethoxy]benzylidene)-2,4-thiazolidinedione;

34

1 5-(4-[2-(N-methyl-N-(2-thiazolyl)amino)ethoxy]benzyl)  
2 -2,4-thiazolidinedione;  
3  
4 5-(4-[2-(N-methyl-N-(2-thiazolyl)amino)ethoxy]  
5 benzylidene)-2,4-thiazolidinedione;  
6  
7 5-[4-(2-(N-methyl-N-(2-(4-phenylthiazolyl))amino)  
8 ethoxy]benzyl]-2,4-thiazolidinedione;  
9  
10 5-(4-[2-(N-methyl-N-(2-(4-phenylthiazolyl))amino)  
11 ethoxy]benzylidene)-2,4-thiazolidinedione;  
12  
13 5-(4-[2-(N-methyl-N-[2-(4-phenyl-5-methylthiazolyl)]  
14 amino)ethoxy]benzyl)-2,4-thiazolidinedione;  
15  
16 5-(4-[2-(N-methyl-N-[2-(4-phenyl-5-methylthiazolyl)]  
17 amino)ethoxy]benzylidene)-2,4-thiazolidinedione;  
18  
19 5-(4-[2-(N-methyl-N-[2-(4-methyl-5-phenylthiazolyl)]  
20 amino)ethoxy]benzyl)-2,4-thiazolidinedione;  
21  
22 5-(4-[2-(N-methyl-N-[2-(4-methyl-5-phenylthiazolyl)]  
23 amino)ethoxy]benzylidene)-2,4-thiazolidinedione;  
24  
25 5-(4-[2-(N-methyl-N-[2-(4-methylthiazolyl)]  
26 amino)ethoxy]benzyl)-2,4-thiazolidinedione;  
27  
28 5-(4-[2-(N-methyl-N-[2-(4-methylthiazolyl)]amino)  
29 ethoxy]benzylidene)-2,4-thiazolidinedione;  
30  
31 5-[4-(2-(N-methyl-N-[2-(5-phenyloxazolyl)]amino)  
32 ethoxy]benzyl]-2,4-thiazolidinedione;  
33

1 5-(4-[2-(N-methyl-N-[2-(5-phenyloxazolyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedione;  
2  
3  
4 5-(4-[2-(N-methyl-N-[2-(4,5-dimethyloxazolyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione;  
5  
6  
7 5-(4-[2-(N-methyl-N-[2-(4,5-dimethyloxazolyl)amino)ethoxy]benzylidene)-2,4-thiazolidinedione;  
8  
9  
10 5-[4-(2-pyrimidinylamino)ethoxy]benzyl]-2,4-thiazolidinedione;  
11  
12  
13 5-[4-(2-pyrimidinylamino)ethoxy]benzylidene]-2,4-thiazolidinedione;  
14  
15  
16 5-(4-[2-(N-acetyl-N-(2-pyrimidinyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione;  
17  
18  
19 5-(4-(2-(N-(2-benzothiazolyl)-N-benzylamino)ethoxy)benzylidene)-2,4-thiazolidinedione;  
20  
21  
22 5-(4-(2-(N-(2-benzothiazolyl)-N-benzylamino)ethoxy)benzyl)-2,4-thiazolidinedione;  
23  
24  
25 5-(4-[3-(N-methyl-N-(2-benzoxazolyl)amino)propoxy]benzyl)-2,4-thiazolidinedione;  
26  
27  
28 5-(4-[3-(N-methyl-N-(2-benzoxazolyl)amino)propoxy]benzylidene)-2,4-thiazolidinedione;  
29  
30  
31 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)-  
32 -2,4-thiazolidinedione;  
33

11/18  
20

- 1    5-[(2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl-  
2    idene)-2,4-thiazolidinedione;  
3  
4    5-[(4-(N-methyl-N-(2-benzoxazolyl)amino)butoxy]benzylidene)-2,4-thiazolidinedione;  
5  
6  
7    5-[(4-(N-methyl-N-(2-benzoxazolyl)amino)butoxy]-  
8    benzyl)-2,4-thiazolidinedione;  
9  
10   5-[(4-[2-(N-(2-benzoxazolyl)amino)ethoxy]benzylidene)-  
11   2,4-thiazolidinedione;  
12  
13   5-[(2-(N-(2-benzoxazolyl)amino)ethoxy]benzyl)-2,  
14   4-thiazolidinedione; and  
15  
16   5-[(4-[2-(N-isopropyl-N-(2-benzoxazolyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione; or a tautomeric form  
17   thereof and/or a pharmaceutically acceptable salt thereof  
18   and/or a pharmaceutically acceptable solvate thereof.  
20